NCT05234593

Brief Summary

The study aims to test the feasibility and acceptability of 1) consumption of EMPowerplus Lightning Sticks, 2) at-home collection of blood and urine samples, and 3) remote visits and completion of online behavioral questionnaires.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 19, 2022

Completed
22 days until next milestone

First Posted

Study publicly available on registry

February 10, 2022

Completed
6 months until next milestone

Study Start

First participant enrolled

August 1, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2023

Completed
Last Updated

April 4, 2025

Status Verified

April 1, 2025

Enrollment Period

6 months

First QC Date

January 19, 2022

Last Update Submit

April 1, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Feasibility measured by count of remaining Sticks

    Feasibility will be determined if consumption of one Lightning Stick daily is achieved when greater than or equal to 80% of provided Sticks were taken. Measured by count of remaining (unused) Sticks.

    week 6

  • Abbreviated Acceptability Rating Profile - 7 questions on a 6-point Likert scale

    Acceptability of taking the Lightning Sticks will be measure through 7 questions with a 6-point Likert-scale, (range: Strongly Disagree to Strongly Agree) Acceptability will be achieved if greater than or equal to 70% of children and parents report that taking powdered multinutrients is acceptable, at or above the Agree range.

    week 6

Secondary Outcomes (7)

  • Feasibility measured by count of participants who provide blood using the Tasso device

    once, at baseline

  • Acceptability measured by a 'yes' response to their preference of using the Tasso device instead of a lab-based blood draw

    once, at baseline

  • Feasibility measured by count of participants who provide the dried urine sample

    once, at baseline

  • Acceptability measured by a 'yes' response to their preference of using the at-home dried urine sample collection method instead of a lab-based urine sample collection method

    once, at baseline

  • Feasibility of remote study visits measured by count of participants who complete all online remote study visits

    week 6

  • +2 more secondary outcomes

Study Arms (1)

Lightning Stick

OTHER

Feasibility and acceptability

Dietary Supplement: EmpowerPlus Lightning Sticks

Interventions

multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue

Lightning Stick

Eligibility Criteria

Age7 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age inclusive of and between 7 and 16 years at the time of enrollment
  • Verbally willing to ingest one EmpowerPlus Lightning Stick daily
  • Attend all virtual study appointments and complete questionnaires
  • Have been previously enrolled in a multinutrient study OR complete a screening to match with participants from that study in terms of age and symptoms of ADHD and emotional dysregulation
  • Be medication and supplementation free (if supplement ingredient is contained in the Lightning Stick) prior to study initiation
  • Willing to collect blood and urine samples, once, at home.

You may not qualify if:

  • Neurological disorder involving brain or other central function (e.g., history of, or suspected, intellectual disability, autism spectrum disorder, epilepsy, multiple sclerosis, narcolepsy) or other major psychiatric condition requiring hospitalization (e.g. significant mood disorder, active suicidal ideation, or psychosis), based on parent/guardian self-report of child's condition
  • Any serious medical condition, including inflammatory bowel disease, history of cancer, kidney or liver disease, hyperthyroidism, diabetes Type I or II
  • Known allergy to any ingredients of the intervention
  • Any known abnormality of mineral metabolism (e.g., Wilson's disease, hemochromatosis)
  • Taking any medication with primarily central nervous system activity, including stimulants used to treat symptoms of ADHD
  • Any disability that would interfere with participant answering questions verbally
  • Non-English speaking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oregon Health & Science University

Portland, Oregon, 97239, United States

Location

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

  • Jeanette Johnstone, PhD

    Oregon Health and Science University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Feasibility
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 19, 2022

First Posted

February 10, 2022

Study Start

August 1, 2022

Primary Completion

February 2, 2023

Study Completion

April 30, 2023

Last Updated

April 4, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations